Compare NECB & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NECB | VNDA |
|---|---|---|
| Founded | 1934 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.0M | 361.4M |
| IPO Year | 2021 | 2005 |
| Metric | NECB | VNDA |
|---|---|---|
| Price | $26.80 | $5.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $30.00 | $14.90 |
| AVG Volume (30 Days) | 31.0K | ★ 715.2K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.12% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | N/A | ★ $216,105,000.00 |
| Revenue This Year | $4.85 | $21.35 |
| Revenue Next Year | $8.45 | $37.40 |
| P/E Ratio | $18.35 | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $19.27 | $4.27 |
| 52 Week High | $28.94 | $9.91 |
| Indicator | NECB | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 55.32 | 40.31 |
| Support Level | $25.87 | $4.94 |
| Resistance Level | $27.53 | $5.55 |
| Average True Range (ATR) | 0.49 | 0.19 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 81.14 | 4.76 |
NorthEast Community Bancorp Inc operates as a community-oriented financial institution. It is principally engaged in the business of attracting deposits and investing those funds into mortgage and commercial loans. It conducts activities throughout the Northeastern United States, including New York, Massachusetts, New Jersey, and Connecticut. The company offers a comprehensive line of banking products and services, including mobile banking as well as commercial real estate loans, commercial construction financing, lines of credit, and term loans. It also offers investment advisory and financial planning services.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.